BG107515A - Therapeutic combination - Google Patents

Therapeutic combination

Info

Publication number
BG107515A
BG107515A BG107515A BG10751503A BG107515A BG 107515 A BG107515 A BG 107515A BG 107515 A BG107515 A BG 107515A BG 10751503 A BG10751503 A BG 10751503A BG 107515 A BG107515 A BG 107515A
Authority
BG
Bulgaria
Prior art keywords
therapeutic combination
combinations
combination
atorvastatin
angina
Prior art date
Application number
BG107515A
Other languages
Bulgarian (bg)
English (en)
Inventor
Charles SHEAR
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107515A publication Critical patent/BG107515A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107515A 2000-08-15 2003-02-03 Therapeutic combination BG107515A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22523800P 2000-08-15 2000-08-15
PCT/IB2001/001309 WO2002013797A2 (fr) 2000-08-15 2001-07-23 Combinaison therapeutique

Publications (1)

Publication Number Publication Date
BG107515A true BG107515A (en) 2003-09-30

Family

ID=22844100

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107515A BG107515A (en) 2000-08-15 2003-02-03 Therapeutic combination

Country Status (27)

Country Link
US (1) US20020035125A1 (fr)
EP (1) EP1309329A2 (fr)
JP (1) JP2004506008A (fr)
KR (1) KR20030069983A (fr)
CN (1) CN1735416A (fr)
AP (1) AP2003002743A0 (fr)
AU (1) AU2001270937A1 (fr)
BG (1) BG107515A (fr)
BR (1) BR0113200A (fr)
CA (1) CA2419406A1 (fr)
CZ (1) CZ2003390A3 (fr)
DZ (1) DZ3409A1 (fr)
EA (1) EA200300155A1 (fr)
EC (1) ECSP034478A (fr)
HR (1) HRP20030104A2 (fr)
HU (1) HUP0303083A3 (fr)
IL (1) IL154348A0 (fr)
IS (1) IS6700A (fr)
MX (1) MXPA03001419A (fr)
NO (1) NO20030725D0 (fr)
PA (1) PA8525301A1 (fr)
PE (1) PE20020340A1 (fr)
SK (1) SK1742003A3 (fr)
SV (1) SV2003000600A (fr)
TN (1) TNSN01125A1 (fr)
UY (1) UY26883A1 (fr)
WO (1) WO2002013797A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
DE60323536D1 (de) * 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2509688A1 (fr) * 2002-12-20 2004-07-08 Pfizer Products Inc. Formes posologiques comprenant un inhibiteur de la cetp et un inhibiteur de la hmg-coa reductase
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2526730A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Derives pyrroliques substitues
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
JP4922924B2 (ja) * 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害薬
CA2601762A1 (fr) * 2005-02-03 2006-08-10 Pfizer Products Inc. Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
EP2379562A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
EP2424521A4 (fr) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (fr) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Méthodes de traitement de l'hypertriglycéridémie
WO2013103958A1 (fr) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
PA8525301A1 (es) 2002-04-25
HUP0303083A2 (hu) 2003-12-29
AP2003002743A0 (en) 2003-03-31
MXPA03001419A (es) 2003-06-06
SV2003000600A (es) 2003-01-13
NO20030725D0 (no) 2003-02-14
TNSN01125A1 (fr) 2005-11-10
HUP0303083A3 (en) 2005-05-30
IL154348A0 (en) 2003-09-17
KR20030069983A (ko) 2003-08-27
EP1309329A2 (fr) 2003-05-14
HRP20030104A2 (en) 2003-04-30
US20020035125A1 (en) 2002-03-21
AU2001270937A1 (en) 2002-02-25
ECSP034478A (es) 2003-03-31
CN1735416A (zh) 2006-02-15
CZ2003390A3 (en) 2004-03-17
IS6700A (is) 2003-01-27
SK1742003A3 (en) 2004-06-08
PE20020340A1 (es) 2002-05-10
DZ3409A1 (fr) 2002-02-21
BR0113200A (pt) 2003-09-16
WO2002013797A2 (fr) 2002-02-21
CA2419406A1 (fr) 2002-02-21
EA200300155A1 (ru) 2003-08-28
WO2002013797A3 (fr) 2003-03-13
JP2004506008A (ja) 2004-02-26
UY26883A1 (es) 2002-03-22

Similar Documents

Publication Publication Date Title
BG107515A (en) Therapeutic combination
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
AU7031500A (en) Therapeutic quinazoline compounds
MXPA01006472A (es) Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU4332500A (en) Enhanced transdermal anesthesia of local anesthetic agents
AU2002234021A1 (en) Method and device for the treatment of vulnerable tissue site
GB0002336D0 (en) Medicaments
AU6910600A (en) Methods for the treatment of mental disorders
MY124786A (en) Bis-arylsulfones
AU8736798A (en) Use of cholinesterase inhibitors for treating attention deficit disorders
AU3366899A (en) Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
WO2001056555A3 (fr) Utilisation d'inhibiteurs de cox-2 dans le traitement de la constipation
MXPA02009705A (es) Nueva combinacion de un betabloqueador y un agente de disminucion de colesterol.
GB9907571D0 (en) Compounds
WO2002039997A3 (fr) Composes modulant ace-2 et procedes d'utilisation associes
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
AUPQ232599A0 (en) Drug for treating fractures
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
IL158186A0 (en) Pharmaceutically active compounds and methods of use
IL139144A0 (en) Mycobacterial inhibitors
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer